Drug intelligence / Profile preview

UI125

Development stage: Preclinical
Lead developer: Korea United Pharm
Modality: Small Molecules
Administration: Oral

Overview

UI125 is an incrementally modified drug (IMD) candidate being developed by Korea United Pharm. It is a small molecule non-steroidal anti-inflammatory drug (NSAID) that is being developed in a new dosage form, likely a controlled-release or improved delivery formulation of an existing NSAID. As an NSAID, UI125 is intended to provide analgesic and anti-inflammatory effects by inhibiting the cyclooxygenase (COX) enzymes, which are responsible for the production of prostaglandins that mediate pain and inflammation. The project is part of Korea United Pharm's focus on developing reformulations of established drugs to enhance patient compliance and therapeutic outcomes. It is currently in the formulation stage of development.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on UI125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI125.

Explore the full profile